Vascular dementia (VaD) is the second major cause of dementia accounting for 15-20 per cent of all dementia cases. VaD is an acquired cognitive impairment due to multiple mini strokes, some of which may be undetectable to the patient. The result is memory loss and a decline in cognitive ability. Currently, viable pharmaceutical options are lacking.
NICM Health Research Institute is investigating whether a standardised Chinese herbal medicine formula, Sailuotong (SLT), can help treat VaD. Results of initial trials show promise in improving memory, learning and daily function.
Due to COVID-19, new recruitment for this clinical trial is temporarily suspended.
For any general trial matters please email the research team at firstname.lastname@example.org
This clinical trial has been approved by the Human Ethics Committees of Western Sydney University (Approval Number: H11554) and South Western Sydney Local Health District Human Research Ethics Committee (2019/ETH08735).
This study will be conducted in multiple sites in NSW, QLD, VIC and SA.
Chief Investigator: Professor Dennis Chang, NICM Health Research Institute.